• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

    8/14/24 7:21:27 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email
    SC 13D/A 1 d49957dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    MeiraGTx Holdings plc

    (Name of Issuer)

    Ordinary Shares, nominal value $0.00003881 per share

    (Title of Class of Securities)

    G59665 102

    (CUSIP Number)

    Alexander Rakitin

    Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

    (646) 205-5340

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 12, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G59665 102

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Advisors LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     12,696,562

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     12,696,562

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     12,696,562

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     16.4%

    14.  

     Type of Reporting Person (See Instructions)

     

     IA


    CUSIP No. G59665 102

     

     1.    

     Names of Reporting Persons.

     

     Joseph Edelman

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     12,696,562

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     12,696,562

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     12,696,562

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     16.4%

    14.  

     Type of Reporting Person (See Instructions)

     

     IN


    CUSIP No. G59665 102

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Life Sciences Master Fund, Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     12,696,562

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     12,696,562

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     12,696,562

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     16.4%

    14.  

     Type of Reporting Person (See Instructions)

     

     CO


    Item 1.

    Security and Issuer

    Item 1 of the Schedule 13D is amended and restated as followed:

    This Schedule 13D relates to the ordinary shares, $0.00003881 nominal value per share (“Ordinary Shares”), of MeiraGTx Holdings plc, an exempted company incorporated under the laws of the Cayman Islands (the “Company”), which has its principal executive offices at 450 East 29th Street, 14th Floor, New York, NY 10016.

     

    Item 2.

    Identity and Background

    Item 2 of the Schedule 13D is amended and restated as followed:

    (a) This Amendment No. 6 to the Schedule 13D is being filed by Perceptive Advisors LLC (“Perceptive Advisors” or “Perceptive”), Joseph Edelman (“Mr. Edelman”) and Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”, and together with Perceptive Advisors and Mr. Edelman, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”). Perceptive Advisors serves as the investment advisor to the Master Fund and Mr. Edelman is the managing member of Perceptive Advisors. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached as Exhibit 1 to the initial Schedule 13D filed June 22, 2018.

    (b) The address of the principal business office of each of the Reporting Persons is 51 Astor Place 10th Floor, New York, NY 10003.

    (c) The principal business of Perceptive Advisors is managing funds in connection with purchasing, holding and selling securities for investment purposes. The principal business of the Master Fund is to invest in securities. The principal occupation of Mr. Edelman is as the managing member of Perceptive Advisors and other related entities.

    (d) During the last five years, none of the Reporting Persons, nor to the Reporting Persons’ knowledge, any of the persons listed on Schedule A to this Amendment No. 6 to Schedule 13D, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws, other than the previously announced settlement order entered into by Perceptive with the Securities and Exchange Commission dated September 6, 2022 (File No. 3-21031).

    (f) Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.

    Schedule A to this Amendment No. 6 to Schedule 13D sets forth the information regarding the directors of the Master Fund.

     

    Item 5.

    Interest in Securities of the Issuer

    Items 5 of the Schedule 13D is amended and supplemented as follows:

     

      (a)

    The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 77,184,187 outstanding Ordinary Shares, as reported by the Issuer in a prospectus supplement filed by the Company pursuant to Rule 424(b)(5) on August 13, 2024.

     

      (b)

    The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. The shares reported include (i) 12,531,103 Ordinary Shares held by the Master Fund, (ii) 115,459 Ordinary Shares issuable upon the exercise of 115,459 vested stock options that the Advisor has rights to pursuant to a management fee offset and (iii) shares issuable upon the settlement of 50,000 deferred share units that the Advisor has rights to pursuant to a management fee offset.

     

      (c)

    On August 12, 2024, the Master Fund purchased 1,250,000 Ordinary Shares at a purchase price of $4.00 per share.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name:   Joseph Edelman
      Title:   Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:  

    /s/ Joseph Edelman

      Name:   Joseph Edelman
      Title:   Managing Member


    Schedule A

    The following sets forth the name, address, principal occupation, citizenship and beneficial ownership of Ordinary Shares (to the extent not pursuant to Item 5(a)) of each director of the Master Fund (to the extent not set forth in Item 2).

     

    Master Fund

    Name and Citizenship

      

    Position

      

    Principal Business Address

      

    Beneficial Ownership of

    Ordinary Shares

    Scott Dakers

    (United Kingdom)

       Director   

    c/o Elian Fiduciary Services (Cayman) Limited

    190 Elgin Avenue, George Town

    Grand Cayman KY1-9007

    Cayman Islands

       None

    Ernest A. Morrison

    (United Kingdom)

       Director   

    Cox Hallett Wilkinson

    Milner House

    18 Parliament Street

    P.O. Box HM 1561

    Hamilton HM FX

    Bermuda

       None

    James Nicholas

    (United States)

       Director   

    c/o GenesisPoint LLC

    30 Old Kings Highway S

    Darien, CT 06820

       None
    Get the next $MGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      8/14/24 6:54:38 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

      LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025, in New Orleans, LA. The posters will be available on the Posters and Publications page of the Company's website. The details of the poster presentations are below: Poster 507: An Ultra-Low Dose of a Localized CNS Gene Therapy for Severe Pediatric ObesityPoster Session: Tuesday, May 13, 6:00-7:30 pm CDTAbstract:Brain-derived neurotrophic factor (BDN

      5/13/25 4:30:00 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Reports First Quarter 2025 Financial and Operational Results

      -  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson's disease -  Gained alignment with FDA on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential BL

      5/13/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

      -  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease -  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the t

      5/9/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MGTX
    SEC Filings

    See more

    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      11/12/24 9:40:33 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      10/18/24 4:47:58 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

      SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

      8/14/24 7:21:27 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc

      SCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      5/14/25 8:30:35 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by MeiraGTx Holdings plc

      10-Q - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:09:19 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:05:14 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CFO & COO Giroux Richard sold $144,000 worth of Ordinary Shares (24,000 units at $6.00), decreasing direct ownership by 3% to 882,494 units (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/22/25 8:54:27 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT & CEO Forbes Alexandria sold $253,650 worth of Ordinary Shares (47,500 units at $5.34), decreasing direct ownership by 3% to 1,408,983 units (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/8/25 9:05:58 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO & COO Giroux Richard

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/7/25 9:05:31 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Landsdowne Labs Names Bryan Laulicht CEO

      Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

      6/13/23 9:05:00 AM ET
      $MGTX
      $AMAG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Pharmaceuticals
    • MeiraGTx Appoints Debra Yu, MD to Board of Directors

      LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen

      4/27/22 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Financials

    Live finance-specific insights

    See more
    • MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

      Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te

      6/27/23 7:30:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023

      LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for

      6/22/23 4:01:00 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

      Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin

      12/13/22 7:30:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

      Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

      7/31/24 6:30:53 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care